Evidence map›Paper›PMID 38587547›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.

Hyungseok Cho, Seok-Soo Byun, Nak-Hoon Son, Jae Il Chung, Won Ik Seo, Chan Ho Lee, Todd M Morgan, Ki-Ho Han, Jae-Seung Chung

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Hyungseok Cho *Department of Nanoscience and Engineering Center for Nano Manufacturing, Inje University, Gimhae, South Korea.ORCID 0000-0002-7044-7700
Seok-Soo Byun *Department of Urology, Seoul National University Bundang Hospital, Seongnam, South Korea.ORCID 0000-0001-7979-9035
Nak-Hoon SonDepartment of Statistics, Keimyung University, Daegu, South Korea.ORCID 0000-0002-6192-8852
Jae Il ChungDepartment of Urology, Busan Paik Hospital, Inje University, Busan, South Korea.ORCID 0000-0002-8114-1125
Won Ik SeoDepartment of Urology, Busan Paik Hospital, Inje University, Busan, South Korea.ORCID 0000-0002-3004-101X
Chan Ho LeeDepartment of Urology, Busan Paik Hospital, Inje University, Busan, South Korea.ORCID 0000-0002-7750-6806
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-1140-0603
Ki-Ho HanDepartment of Nanoscience and Engineering Center for Nano Manufacturing, Inje University, Gimhae, South Korea.ORCID 0000-0002-9102-1581
Jae-Seung ChungDepartment of Urology, Haeundae Paik Hospital, Inje University, Busan, South Korea.ORCID 0000-0001-9672-2216

Funding

National Research Foundation of Korea (NRF) NRF-2021R1A2C4001594National Research Foundation of Korea (NRF) NRF-2021R1C1C2007117National Research Foundation of Korea (NRF) NRF-2022R1A2C1002939
6 · The paper itself

Abstract

purposeProstate-specific membrane antigen (PSMA)-based images, which visually quantify PSMA expression, are used to determine prostate cancer micrometastases. This study evaluated whether a circulating tumor cell (CTC)-based transcript platform, including PSMA mRNA, could help identify potential prognostic markers in prostate cancer. EXPERIMENTAL

designWe prospectively enrolled 21 healthy individuals and 247 patients with prostate cancer [localized prostate cancer (LPCa), n = 94; metastatic hormone-sensitive prostate cancer (mHSPC), n = 44; and metastatic castration-resistant prostate cancer (mCRPC), n = 109]. The mRNA expression of six transcripts [PSMA, prostate-specific antigen (PSA), AR, AR-V7, EpCAM, and KRT 19] from CTCs was measured, and their relationship with biochemical recurrence (BCR) in LPCa and mCRPC progression-free survival (PFS) rate in mHSPC was assessed. PSA-PFS and radiological-PFS were also calculated to identify potential biomarkers for predicting androgen receptor signaling inhibitor (ARSI) and taxane-based chemotherapy resistance in mCRPC.

resultsCTC detection rates were 75.5%, 95.3%, and 98.0% for LPCa, mHSPC, and mCRPC, respectively. In LPCa, PSMA [hazard ratio (HR), 3.35; P = 0.028) and PSA mRNA (HR, 1.42; P = 0.047] expressions were associated with BCR. Patients with mHSPC with high PSMA (HR, 4.26; P = 0.020) and PSA mRNA (HR, 3.52; P = 0.042) expressions showed significantly worse mCRPC-PFS rates than those with low expression. Increased PSA and PSMA mRNA expressions were significantly associated with shorter PSA-PFS and radiological PFS in mCPRC, indicating an association with drug resistance.

conclusionsPSMA and PSA mRNA expressions are associated with BCR in LPCa. In advanced prostate cancer, PSMA and PSA mRNA can also predict rapid progression from mHSPC to mCRPC and ARSI or taxane-based chemotherapy resistance.

Indexed as

Antigens, SurfaceBiomarkers, TumorGlutamate Carboxypeptidase IINeoplasm StagingNeoplastic Cells, CirculatingProstate-Specific AntigenAgedAged, 80 and overGene Expression Regulation, NeoplasticHumansKallikreinsMaleMiddle AgedPrognosisProspective StudiesProstatic NeoplasmsAntigens, SurfaceBiomarkers, TumorFOLH1 protein, humanGlutamate Carboxypeptidase IIKallikreinsKLK3 protein, humanProstate-Specific AntigenRNA, Messenger

Identifiers

PMID38587547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.